These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19330328)

  • 1. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
    Terasaki Y; Shichijo S; Niu Y; Komatsu N; Noguchi M; Todo S; Itoh K
    Cancer Immunol Immunother; 2009 Nov; 58(11):1877-85. PubMed ID: 19330328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
    Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
    Takedatsu H; Shichijo S; Katagiri K; Sawamizu H; Sata M; Itoh K
    Clin Cancer Res; 2004 Feb; 10(3):1112-20. PubMed ID: 14871991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco MA; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2015 May; 26(1):133-8. PubMed ID: 25819666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
    Naito M; Komohara Y; Ishihara Y; Noguchi M; Yamashita Y; Shirakusa T; Yamada A; Itoh K; Harada M
    Br J Cancer; 2007 Dec; 97(12):1648-54. PubMed ID: 18043580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
    Minami T; Matsueda S; Takedatsu H; Tanaka M; Noguchi M; Uemura H; Itoh K; Harada M
    Cancer Immunol Immunother; 2007 May; 56(5):689-98. PubMed ID: 16937115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients.
    Komatsu N; Terasaki Y; Moriya F; Suekane S; Noguchi M; Todo S; Itoh K; Shichijo S
    Exp Ther Med; 2010 Sep; 1(5):833-839. PubMed ID: 22993607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
    Mohamed ER; Naito M; Terasaki Y; Niu Y; Gohara S; Komatsu N; Shichijo S; Itoh K; Noguchi M
    Int J Oncol; 2009 Feb; 34(2):529-36. PubMed ID: 19148489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
    Matsueda S; Takedatsu H; Sasada T; Azuma K; Ishihara Y; Komohara Y; Noguchi M; Shichijo S; Itoh K; Harada M
    J Immunother; 2007 Apr; 30(3):274-81. PubMed ID: 17414318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
    Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients.
    Niu Y; Terasaki Y; Komatsu N; Noguchi M; Shichijo S; Itoh K
    Cancer Sci; 2009 Nov; 100(11):2167-74. PubMed ID: 19689476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
    Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
    J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals.
    Liu J; Zhang S; Tan S; Yi Y; Wu B; Cao B; Zhu F; Wang C; Wang H; Qi J; Gao GF
    J Virol; 2012 Dec; 86(24):13281-94. PubMed ID: 23015716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
    Kobayashi K; Noguchi M; Itoh K; Harada M
    Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
    Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
    Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C.
    Chang KM; Gruener NH; Southwood S; Sidney J; Pape GR; Chisari FV; Sette A
    J Immunol; 1999 Jan; 162(2):1156-64. PubMed ID: 9916747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
    Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
    Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.